Adagio Medical Announces Preliminary Study Results Showing 97 Percent Acute Effectiveness for ULTC in Ventricular Tachycardia

Reuters10-11

Adagio Medical Announces Preliminary Study Results Showing 97 Percent Acute Effectiveness for ULTC in Ventricular Tachycardia

Adagio Medical Holdings Inc. has announced preliminary acute safety and efficacy results from its FULCRUM-VT U.S. Pivotal Study, evaluating the company's Ultralow Temperature Cryoablation (ULTC) system for the treatment of sustained monomorphic ventricular tachycardia (SMVT) in patients with both ischemic and non-ischemic cardiomyopathy. The results, which are being presented at the 20th Annual International Symposium on Ventricular Arrhythmias in Philadelphia on October 10, 2025, show a 97.4% acute clinical success rate, defined as non-inducibility of target ventricular arrhythmias, and a 2.5% rate of major adverse events. The study included 207 patients across 19 sites in the United States and Canada.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251010655037) on October 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2574410400?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-11 03:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574410400","market":"nz","top_or_hot":-1,"title":"Adagio Medical Announces Preliminary Study Results Showing 97 Percent Acute Effectiveness for ULTC in Ventricular Tachycardia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagio Medical Announces Preliminary Study Results Showing 97 Percent Acute Effectiveness for ULTC in Ventricular Tachycardia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagio Medical Holdings Inc. has announced preliminary acute safety and efficacy results from its FULCRUM-VT U.S. Pivotal Study, evaluating the company's Ultralow Temperature Cryoablation (ULTC) system for the treatment of sustained monomorphic ventricular tachycardia (SMVT) in patients with both ischemic and non-ischemic cardiomyopathy. The results, which are being presented at the 20th Annual International Symposium on Ventricular Arrhythmias in Philadelphia on October 10, 2025, show a 97.4% acute clinical success rate, defined as non-inducibility of target ventricular arrhythmias, and a 2.5% rate of major adverse events. The study included 207 patients across 19 sites in the United States and Canada.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251010655037) on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagio Medical Announces Preliminary Study Results Showing 97 Percent Acute Effectiveness for ULTC in Ventricular Tachycardia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagio Medical Announces Preliminary Study Results Showing 97 Percent Acute Effectiveness for ULTC in Ventricular Tachycardia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-11 03:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagio Medical Announces Preliminary Study Results Showing 97 Percent Acute Effectiveness for ULTC in Ventricular Tachycardia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagio Medical Holdings Inc. has announced preliminary acute safety and efficacy results from its FULCRUM-VT U.S. Pivotal Study, evaluating the company's Ultralow Temperature Cryoablation (ULTC) system for the treatment of sustained monomorphic ventricular tachycardia (SMVT) in patients with both ischemic and non-ischemic cardiomyopathy. The results, which are being presented at the 20th Annual International Symposium on Ventricular Arrhythmias in Philadelphia on October 10, 2025, show a 97.4% acute clinical success rate, defined as non-inducibility of target ventricular arrhythmias, and a 2.5% rate of major adverse events. The study included 207 patients across 19 sites in the United States and Canada.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251010655037) on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDLkZ0rM:1","article_id":"2574410400","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574410400","pubTimestamp":1760125214,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adagio Medical Announces Preliminary Study Results Showing 97 Percent Acute Effectiveness for ULTC in Ventricular Tachycardia. Adagio Medical Holdings Inc. has announced preliminary acute safety and efficacy results from its FULCRUM-VT U.S. Pivotal Study, evaluating the company's Ultralow Temperature Cryoablation  system for the treatment of sustained monomorphic ventricular tachycardia  in patients with both ischemic and non-ischemic cardiomyopathy. The results, which are being presented at the 20th Annual International Symposium on Ventricular Arrhythmias in Philadelphia on October 10, 2025, show a 97.4% acute clinical success rate, defined as non-inducibility of target ventricular arrhythmias, and a 2.5% rate of major adverse events. The study included 207 patients across 19 sites in the United States and Canada.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","XTNT":"Xtant Medical Holdings Inc","ADGM":"Adagio Medical Holdings, Inc.","BK4198":"医疗保健用品"},"translate_title":"Adagio Medical宣布初步研究结果显示ULTC治疗室性心动过速的急性有效性为97%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADGM":0.9,"XTNT":0.9},"content_text":"Adagio Medical Announces Preliminary Study Results Showing 97 Percent Acute Effectiveness for ULTC in Ventricular Tachycardia\n    \n\n        Adagio Medical Holdings Inc. has announced preliminary acute safety and efficacy results from its FULCRUM-VT U.S. Pivotal Study, evaluating the company's Ultralow Temperature Cryoablation (ULTC) system for the treatment of sustained monomorphic ventricular tachycardia (SMVT) in patients with both ischemic and non-ischemic cardiomyopathy. The results, which are being presented at the 20th Annual International Symposium on Ventricular Arrhythmias in Philadelphia on October 10, 2025, show a 97.4% acute clinical success rate, defined as non-inducibility of target ventricular arrhythmias, and a 2.5% rate of major adverse events. The study included 207 patients across 19 sites in the United States and Canada.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251010655037) on October 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2574410400","isCrawlerRequest":true}